Axogen (AXGN) closed at $55.93 on November 13, 2026, up 1.0% from the previous close, on volume of 1,309,444 shares (30-day average 1,896,262).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Covered Call | 20-Nov-26 35 C +500 Stock | 2,934 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
AxoGen Earnings Call Highlights Growth and BioCircuit Momentum
TipRanks (Thu, 12-Nov 7:22 PM ET)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and AxoGen (AXGN)
TipRanks (Thu, 12-Nov 7:20 AM ET)
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Axogen posts 26.2% revenue growth as cash climbs to $350.1 million after an upsized offering
Market Chameleon (Wed, 28-Oct 3:57 AM ET)
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Globe Newswire (Wed, 28-Oct 7:02 AM ET)
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Globe Newswire (Wed, 14-Oct 7:00 AM ET)
Wound Care Stocks Are Posting Double-Digit Growth. Here's Why.
Globe Newswire (Tue, 6-Oct 9:06 AM ET)
Globe Newswire (Thu, 1-Oct 5:19 PM ET)
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Globe Newswire (Thu, 10-Sep 6:01 AM ET)
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Globe Newswire (Thu, 10-Sep 6:00 AM ET)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Axogen trades on the NASDAQ stock market under the symbol AXGN.
As of November 13, 2026, AXGN stock price climbed to $55.93 with 1,309,444 million shares trading.
AXGN has a beta of 0.98, meaning it tends to be less sensitive to market movements. AXGN has a correlation of 0.04 to the broad based SPY ETF.
AXGN has a market cap of $3.34 billion. This is considered a Mid Cap stock.
Last quarter Axogen reported $76 million in Revenue and $.21 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.11.
In the last 3 years, AXGN traded as high as $59.72 and as low as $5.41.
The top ETF exchange traded funds that AXGN belongs to (by Net Assets): IWM, VTI, IWO, VXF, SCHA.
AXGN has outperformed the market in the last year with a price return of +132.7% while the SPY ETF gained +13.4%. AXGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.4% and +13.3%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
AXGN support price is $53.42 and resistance is $57.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXGN shares will trade within this expected range on the day.